<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109380">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02055664</url>
  </required_header>
  <id_info>
    <org_study_id>MIREK 2013</org_study_id>
    <nct_id>NCT02055664</nct_id>
  </id_info>
  <brief_title>The Tap Block Technique Via the Anterior Approach in Elective Surgery of the Spine</brief_title>
  <acronym>TAPBloc Rachis</acronym>
  <official_title>THE TAP BLOCK TECHNIQUE VIA THE ANTERIOR APPROACH IN ELECTIVE SURGERY OF THE SPINE: Prospective, Randomised, Double Blind Trial, Comparing TAP BLOCK With Continuous Infiltration of Ropivacaine Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-centre, randomised, double-blind trial, comparing TAP block
      with continuous infiltration of ropivacaine versus placebo.

      Procedure:

      Once consent has been obtained, patients will be randomised into one of the two groups:
      Ropivacaine or Placebo. At the end of the operation, the TAP block will be implemented via a
      catheter inserted by the anaesthetist.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind</study_design>
  <primary_outcome>
    <measure>Consumption of morphine in mg</measure>
    <time_frame>First 48 hours following the surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensity of pain</measure>
    <time_frame>First 48 hours following the surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Elective Surgery of the Spine by Laparotomy</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.2%</intervention_name>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorure de sodium 0.9%</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 yo who have provided written informed consent

          -  Patients with an indication for elective spinal surgery using laparotomy

          -  Patients with national health insurance  cover

        Exclusion Criteria:

          -  Adults under guardianship

          -  Pregnant or breast-feeding women

          -  allergies or contra-indication for paracetamol, morphine-based drugs

          -  Contra-indication for ropivacaine

          -  Contra-indication for sodium chloride

          -  inability to understand PCA (patient-controlled anaesthesia)

          -  Hypersensitivity to ropivacaine or to other aminoamide local anaesthetics

          -  Hypovolemia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Sebastien MIREK</last_name>
    <phone>3.80.29.30.31</phone>
    <phone_ext>+33</phone_ext>
    <email>sebastien.mirek@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien MIREK</last_name>
      <phone>3.80.29.30.31</phone>
      <phone_ext>+33</phone_ext>
      <email>sebastien.mirek@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>February 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
